Format

Send to:

Choose Destination
See comment in PubMed Commons below
Endocrinol Metab Clin North Am. 2011 Sep;40(3):509-18, viii. doi: 10.1016/j.ecl.2011.05.006. Epub 2011 Jul 12.

Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.

Author information

  • 1Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. wendy.chen@channing.harvard.edu

Abstract

Many women take hormone therapy (HT) for menopausal symptom relief. Studies have tried to clarify whether various factors can modify the risk of HT, such as the age at initiation, dose, duration, or type of HT, or characteristics of the individual, such as family history or body mass index. The relative risks of breast cancer associated with HT across various subgroups of women should be considered similar, but absolute risks can vary significantly among women and this may inform individual decision making. For breast cancer survivors, systemic HT should be discouraged.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21889717
[PubMed - indexed for MEDLINE]
PMCID:
PMC3167091
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk